QuantuMDx: Neil Butler

Sep 13, 2019

UK-based QuantuMDx has appointed Neil Butler as its non-executive director. Butler currently serves on the board of Nidor Dx, Radisens, and Spectromics. He previously served as chair and non-executive director for Atlast Genetics/Binx Health and Genomic Vision.

Breaking News

NanoString, A*Star, Next Level Genomics to Launch Spatial Biology Laboratory in Singapore
FDA Approves Entrogen's RAS Mutation Detection Kit as CDx for Vectibix
Cancer Predisposition Variants Increase Secondary Cancer Mortality Risk in Pediatric Survivors
BostonGene, Johns Hopkins University Partner for Multiple Cancer Clinical Research Projects
KromaTid, Noble Life Sciences Ink Distribution, OEM Agreement

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.